Get the Stockscreener App
63.16
1.37%
-0.88
After Hours:
63.16
Ionis Pharmaceuticals Inc stock is traded at $63.16, with a volume of 1.42M.
It is down -1.37% in the last 24 hours and up +52.52% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$64.04
Open:
$63.85
24h Volume:
1.42M
Relative Volume:
0.60
Market Cap:
$10.07B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-20.78
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+3.15%
1M Performance:
+52.52%
6M Performance:
+89.05%
1Y Performance:
+53.97%
1-Day Range:
$63.07
$64.61
1-Week Range:
$59.36
$64.72
52-Week Range:
$23.95
$64.72
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
63.16 | 10.20B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis pharmaceuticals celebrates 10 years of adaptive event for rare diseases - Investing.com
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases - Yahoo Finance
Ionis gets FDA breakthrough therapy status for angelman syndrome drug - MSN
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 6,000 Shares of Stock - MarketBeat
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug - Reuters
Raymond James Financial Inc. Boosts Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Arrowhead, Ionis Sue Each Other Over Rare Fat Disorder Drugs - Bloomberg Law News
Arrowhead sues Ionis over patent dispute related to lead asset - Seeking Alpha
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year HighStill a Buy? - MarketBeat
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Business Wire
Edmond DE Rothschild Holding S.A. Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Stock Holdings Raised by Exome Asset Management LLC - MarketBeat
Ionis Stock: Renewed Assault On $100.00 Per Share (NASDAQ:IONS) - Seeking Alpha
Adage Capital Partners GP L.L.C. Purchases 800,600 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis pharma EVP Bennett sells $357k in IONS stock By Investing.com - Investing.com UK
Ionis Pharmaceuticals at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com Canada
FDA Grants Breakthrough Therapy Designation to Ionis (IONS) Drug - GuruFocus
Ionis Pharmaceuticals stock hits 52-week high at 62.28 USD By Investing.com - Investing.com Canada
Aug Volume: Can Ionis Pharmaceuticals Inc. be recession proofMarket Rally & Capital Efficiency Focused Ideas - Lancaster City Council
Ionis Rare Neurological Disease Candidate Receives FDA Breakthrough StatusIonis Pharmaceuticals (NASDAQ:IONS) - Benzinga
Ionis Pharmaceuticals stock hits 52-week high at 62.28 USD - Investing.com
Ionis announces pricing of $500.3 million public offering - MSN
Health Stocks Shift As UnitedHealth Rises And PACS Drops - Finimize
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' ION582 - GuruFocus
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome - Business Wire
Ionis Pharmaceuticals (NASDAQ:IONS) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Ionis to host investors and analysts for Innovation Day 2025 - BioSpace
Ionis Pharmaceuticals at H.C. Wainwright: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
Ionis to host investors and analysts for Innovation Day 2025 | I - GuruFocus
Ionis Pharmaceuticals (IONS) Is Up 43.6% After Positive Phase 3 Olezarsen Results in Severe Hypertriglyceridemia – Has the Bull Case Changed? - Yahoo Finance
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $45.00 Price Target at The Goldman Sachs Group - MarketBeat
What are Ionis Pharmaceuticals Inc.’s earnings expectationsTrade Signal Summary & High Accuracy Investment Entry Signals - beatles.ru
Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $96.00 Price Target at Jefferies Financial Group - MarketBeat
HC Wainwright Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Does Ionis Pharmaceuticals Inc. stock have upside surprise potentialQuarterly Growth Report & Expert-Curated Trade Recommendations - خودرو بانک
Ionis Pharma director Loscalzo sells $962k in shares By Investing.com - Investing.com Australia
What are analysts’ price targets for Ionis Pharmaceuticals Inc.2025 Key Lessons & Precise Buy Zone Tips - خودرو بانک
Ionis Pharma EVP Baroldi sells $1.95m in shares By Investing.com - Investing.com Australia
Ionis Pharmaceuticals director Wender sells $1.6m in shares By Investing.com - Investing.com South Africa
Ionis pharma EVP Devers sells $192,942 in IONS stock By Investing.com - Investing.com South Africa
Is Ionis Pharmaceuticals Inc. a potential multi baggerJuly 2025 Price Swings & Long-Term Safe Return Strategies - خودرو بانک
What is the earnings history of Ionis Pharmaceuticals Inc.Quarterly Profit Report & Smart Swing Trading Techniques - خودرو بانک
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
How sentiment analysis helps forecast Ionis Pharmaceuticals Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Ionis Pharmaceuticals Stock (IONS) Opinions on Olezarsen Trial Results and FDA Approval - Quiver Quantitative
Ionis pharma EVP O’Neil sells $5.39 million in IONS stock - Investing.com Nigeria
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 38% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Ionis Pharma EVP Schneider sells $1.19m in shares By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):